Free Trial

4basebio (4BB) Competitors

GBX 1,405
-5.00 (-0.35%)
(As of 05/20/2024 ET)

4BB vs. HVO, FARN, AVCT, BVXP, FUM, SCLP, POLB, REDX, ETX, and OXB

Should you be buying 4basebio stock or one of its competitors? The main competitors of 4basebio include hVIVO (HVO), Faron Pharmaceuticals Oy (FARN), Avacta Group (AVCT), Bioventix (BVXP), Futura Medical (FUM), Scancell (SCLP), Poolbeg Pharma (POLB), Redx Pharma (REDX), e-therapeutics (ETX), and Oxford Biomedica (OXB). These companies are all part of the "biotechnology" industry.

4basebio vs.

hVIVO (LON:HVO) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, community ranking, earnings, institutional ownership, analyst recommendations, risk and profitability.

hVIVO has a net margin of 27.47% compared to hVIVO's net margin of 0.00%. 4basebio's return on equity of 59.09% beat hVIVO's return on equity.

Company Net Margins Return on Equity Return on Assets
hVIVO27.47% 59.09% 9.58%
4basebio N/A -97.29%-35.08%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
hVIVO
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
4basebio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

In the previous week, 4basebio's average media sentiment score of 0.00 equaled hVIVO'saverage media sentiment score.

Company Overall Sentiment
hVIVO Neutral
4basebio Neutral

14.2% of hVIVO shares are owned by institutional investors. Comparatively, 9.0% of 4basebio shares are owned by institutional investors. 39.2% of hVIVO shares are owned by company insiders. Comparatively, 62.2% of 4basebio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

hVIVO received 123 more outperform votes than 4basebio when rated by MarketBeat users.

CompanyUnderperformOutperform
hVIVOOutperform Votes
123
69.89%
Underperform Votes
53
30.11%
4basebioN/AN/A

hVIVO has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, 4basebio has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.

hVIVO has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
hVIVO£58.67M3.08£16.11M£0.021,330.00
4basebio£311K578.72-£6.28M-£0.51-2,754.90

Summary

hVIVO beats 4basebio on 9 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding 4BB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

4BB vs. The Competition

Metric4basebioBiotechnology IndustryMedical SectorLON Exchange
Market Cap£179.98M£228.15M£5.06B£1.54B
Dividend YieldN/A3.42%45.59%8.43%
P/E Ratio-2,754.90247.17175.541,829.85
Price / Sales578.7214,911.422,440.30314,792.31
Price / Cash16.0811.3232.9634.62
Price / Book50.185.735.042.70
Net Income-£6.28M-£37.44M£103.32M£171.96M
7 Day Performance-0.71%-0.01%1.03%5.74%
1 Month Performance35.75%5.81%5.76%5.86%
1 Year Performance153.15%1.82%7.42%12.42%

4basebio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HVO
hVIVO
0 of 5 stars
GBX 27.47
-0.1%
N/A+63.7%£186.90M£58.67M1,373.50N/A
FARN
Faron Pharmaceuticals Oy
0 of 5 stars
GBX 240
+6.7%
N/A-10.6%£172.82M£-725,000.00-585.3734News Coverage
AVCT
Avacta Group
0 of 5 stars
GBX 44.25
-1.1%
N/A-61.4%£158.88M£23.25M-491.67120
BVXP
Bioventix
0 of 5 stars
GBX 4,375
flat
N/A+17.9%£228.38M£13.60M2,684.0512
FUM
Futura Medical
0 of 5 stars
GBX 39.85
-0.4%
N/A-8.9%£120.13M£3.10M-1,992.5012
SCLP
Scancell
0 of 5 stars
GBX 10.10
flat
N/A-35.4%£93.83M£5.27M-1,010.0051
POLB
Poolbeg Pharma
0 of 5 stars
GBX 13.15
-3.0%
N/A+68.5%£65.75MN/A-1,315.0012
REDX
Redx Pharma
0 of 5 stars
GBX 15
+31.6%
N/A-53.1%£58.35M£4.20M-150.00101Gap Up
High Trading Volume
ETX
e-therapeutics
0 of 5 stars
GBX 9
-6.7%
N/A-27.3%£52.59M£295,000.00-450.0034High Trading Volume
OXB
Oxford Biomedica
1.7609 of 5 stars
GBX 322
+0.6%
GBX 498.75
+54.9%
-27.0%£322M£119.02M-503.13891

Related Companies and Tools

This page (LON:4BB) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners